

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1-32. (Cancelled)

33. (Previously Presented) A composition comprising a pure form of a proenzyme for the protease activating blood clotting factor VII, optionally further comprising one or more substances chosen from:

- a) complexing agents of divalent ions;
- b) amino acids;
- c) sugars;
- d) detergents;
- e) alcohols;
- f) albumin;
- g) gelatin;
- h) fibronectin;
- i) vitronectin;
- j) reductants; and
- k) protease inhibitors;

wherein the amino acid sequence of the protease comprises the following peptide sequences: IYGGFKSTAGKHP (SEQ ID NO:1), LLESLDPDXTPD (SEQ ID NO:2), EFHEQSFRVEKI (SEQ ID NO:3), and SKFTXAXPXQFK (SEQ ID NO:4), wherein X denotes an unidentified amino acid.

34. (Previously Presented) The composition according to claim 33, comprising one or more complexing agents of divalent ions chosen from one or more of EDTA, EGTA, and citrate.

35. (Previously Presented) The composition according to claim 34, wherein the one or more complexing agents of divalent ions comprises EDTA.
36. (Previously Presented) The composition according to claim 34, further comprising one or more substances chosen from amino acids, protease inhibitors, and albumin.
37. (Previously Presented) The composition according to claim 36, comprising at least one amino acid comprising arginine and optionally one or more additional amino acids.
38. (Previously Presented) The composition according to claim 36, comprising at least one protease inhibitor comprising aprotinin and optionally one or more additional protease inhibitors.
39. (Previously Presented) The composition according to claim 33, comprising one or more amino acids chosen from one or more of glutamate, arginine, lysine, and glycine.
40. (Previously Presented) The composition according to claim 33, comprising one or more sugars chosen from one or more of glucose, arabinose, mannose, and mannitol.
41. (Previously Presented) The composition according to claim 33, comprising one or more alcohols chosen from one or both of ethylene glycol and polyethylene glycol.
42. (Previously Presented) The composition according to claim 33, comprising one or more reductants chosen from one or more of dithiothreitol, mercaptoethanol, or cysteine.

43. (Previously Presented) The composition according to claim 33, comprising one or more protease inhibitors chosen from one or more of aprotinin, α 2-antiplasmin, C1-esterase inhibitor, inter- α -trypsin inhibitor, and antithrombin III/heparin inhibitor.
44. (Previously Presented) The composition according to claim 43, wherein the one or more protease inhibitors comprise aprotinin.
45. (Previously Presented) The composition according to claim 43, further comprising one or more amino acids.
46. (Previously Presented) The composition according to claim 43, further comprising albumin.
47. (Previously Presented) The composition according to claim 33, wherein the composition acts as a biological test reagent.
48. (Previously Presented) A composition comprising a mixture of a pure form of the protease activating blood clotting factor VII and a pure form of a proenzyme of said protease, and optionally further comprising one or more substances chosen from:
 - a) complexing agents of divalent ions;
 - b) amino acids;
 - c) sugars;
 - d) detergents;
 - e) alcohols;
 - f) albumin;
 - g) gelatin;
 - h) fibronectin;
 - i) vitronectin;
 - j) reductants; and

k) protease inhibitors;

wherein the amino acid sequence of the protease comprises the following peptide sequences: IYGGFKSTAGKHP (SEQ ID NO:1), LLESLDPDXTPD (SEQ ID NO:2), EFHEQSFRVEKI (SEQ ID NO:3), and SKFTXAXPXQFK (SEQ ID NO:4), wherein X denotes an unidentified amino acid.

49. (Previously Presented) The composition according to claim 48, comprising one or more complexing agents of divalent ions chosen from one or more of EDTA, EGTA, and citrate.
50. (Previously Presented) The composition according to claim 49, wherein the one or more complexing agents of divalent ions comprises EDTA.
51. (Previously Presented) The composition according to claim 49, further comprising one or more substances chosen from amino acids, protease inhibitors, and albumin.
52. (Previously Presented) The composition according to claim 51, comprising at least one amino acid comprising arginine and optionally comprising one or more additional amino acids.
53. (Previously Presented) The composition according to claim 51, comprising at least one protease inhibitor comprising aprotinin and optionally comprising one or more additional protease inhibitors.
54. (Previously Presented) The composition according to claim 48, comprising one or more amino acids chosen from one or more of glutamate, arginine, lysine, and glycine.

- 55. (Previously Presented) The composition according to claim 48, comprising one or more sugars chosen from one or more of glucose, arabinose, mannose, and mannitol.
- 56. (Previously Presented) The composition according to claim 48, comprising one or more alcohols chosen from one or both of ethylene glycol and polyethylene glycol.
- 57. (Previously Presented) The composition according to claim 48, comprising one or more reductants chosen from one or more of dithiothreitol, mercaptoethanol or cysteine.
- 58. (Previously Presented) The composition according to claim 48, comprising one or more protease inhibitors chosen from one or more of aprotinin, α 2-antiplasmin, C1-esterase inhibitor, inter- α -trypsin inhibitor, and antithrombin III/heparin inhibitor.
- 59. (Previously Presented) The composition according to claim 58, wherein the one or more protease inhibitors comprise aprotinin.
- 60. (Previously Presented) The composition according to claim 58, further comprising one or more amino acids.
- 61. (Previously Presented) The composition according to claim 58, further comprising albumin.
- 62. (Previously Presented) The composition according to claim 48, wherein the composition acts as a biological test reagent.
- 63.-75. (Cancelled)